BioSpace News Archive

Alfasigma S.p.A, and Intercept Pharmaceuticals, Inc. announced that they have entered into a definitive merger agreement under which Alfasigma has agreed to acquire Intercept for $19.00 per share in cash.

Sirius Medical a global leader in Value-Based Healthcare and Surgical Marker Navigation, announced that GE HealthCare will showcase Pintuition at the upcoming Annual European Society of Breast Imaging (EUSOBI) Conference 2023.

Mesentech, a biotech company developing novel tissue-selective therapies to treat bone diseases, announced today that it has dosed the first patients in its Phase 1 study for MES1022, a bone regeneration drug which enhances efficacy and avoids systemic exposure and side-effects by selectively distributing to bony tissues.

Sonendo , Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that on September 25, 2023, the Compensation Committee of Sonendo’s Board of Directors granted restricted stock unit awards covering an aggregate of 14,000 shares of its common stock to two new, non-executive employees to induce them to join the company.

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the expansion into outpatient ambulatory centers to accelerate clinical trial recruitment.

Mythic Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mythic’s investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression.

LIXTE Biotechnology Holdings, Inc. announced that Bas van der Baan has been named as President and Chief Executive Officer of the Company, and as Vice Chairman of the Board of Directors, effective as of September 26, 2023.

Ambrx Biopharma Inc., Ambrx, announced that it will host an in-person key opinion leader event during the European Society for Medical Oncology Congress 2023.

YS Biopharma Co., Ltd. today announced that it has enrolled the first subject in its Phase 3 clinical trial (the “Phase 3 Trial” or the “Trial”) of the Company’s PIKA Rabies Vaccine.

Cantex Pharmaceuticals, Inc. today announced the initiation of a Phase 1/2 study to assess the safety and efficacy of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.